CLGM
SYRE icon

Capitolis Liquid Global Markets’s Spyre Therapeutics SYRE Stock Holding History

Capitolis Liquid Global Markets’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-183,000
Closed -$2.74M – 310
2025
Q2 		$2.74M Buy
+183,000
New +$2.71M 0.02% 224

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Capitolis Liquid Global Markets's SYRE Position: Q3 2025 in Review

Capitolis Liquid Global Markets sold out of Spyre Therapeutics (SYRE) in Q3 2025, closing a stake of 183,000 shares — an estimated $2.74M sold.

Capitolis Liquid Global Markets first reported a position in SYRE in Q2 2025 and held it in 1 quarter. The position peaked at $2.74M in Q2 2025. 137 funds tracked by Wall St. Rank hold SYRE as of Q3 2025.

  • Capitolis Liquid Global Markets reported no remaining Spyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capitolis Liquid Global Markets sold 183,000 Spyre Therapeutics shares in Q3 2025, an estimated $2.74M.
  • Capitolis Liquid Global Markets first reported a position in Spyre Therapeutics in Q2 2025 and held it in 1 quarter.
  • Capitolis Liquid Global Markets's Spyre Therapeutics position peaked at $2.74M in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2025.

Based on Capitolis Liquid Global Markets's 13F filing for Q3 2025, filed 14 Nov 2025.